- Home
- RC vs ABEO Comparison
RC vs ABEO Comparison
Compare RC & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RC | ABEO |
|---|---|---|
| Founded | 2007 | 1974 |
| Country | United States | United States |
| Employees | 475 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.9M | 280.2M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | RC | ABEO |
|---|---|---|
| Price | $1.61 | $4.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.81 | ★ $18.75 |
| AVG Volume (30 Days) | ★ 2.5M | 1.4M |
| Earning Date | 05-07-2026 | 03-17-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | $67.36 | $112.53 |
| P/E Ratio | ★ N/A | $4.25 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $1.50 | $3.93 |
| 52 Week High | $5.24 | $7.54 |
Technical Indicators
Market Signals| Indicator | RC | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 31.52 |
| Support Level | $1.53 | $4.00 |
| Resistance Level | $2.15 | $5.62 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 27.27 | 2.29 |
Price Performance
Historical ComparisonAbout RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.